Online inquiry

IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3464MR)

This product GTTS-WQ3464MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3464MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1923MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ12640MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ14408MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ12383MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ5510MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ2581MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ3002MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ15667MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VB6-845
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW